Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the ...
Read More
Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.
Read Less
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $29.99, good condition, Sold by Wonder Book - Member ABAA/ILAB rated 5.0 out of 5 stars, ships from Frederick, MD, UNITED STATES, published 1996 by Humana.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Good. Good condition. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $47.94, like new condition, Sold by Monarchy Books rated 4.0 out of 5 stars, ships from Toronto, ON, CANADA, published 1997 by Humana Pr Inc.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Size: 9x7x1; Hardcover, pictorial boards. 451 pages with the index. tetxtbook binding. based on your address. -We can ship from USA and Canada. Specializing in academic, collectible and historically significant, providing the utmost quality and customer service satisfaction. For any questions feel free to email us.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $49.42, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Santa Clarita, CA, UNITED STATES, published 1996 by Humana.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $94.00, like new condition, Sold by Marsarbooks rated 5.0 out of 5 stars, ships from Cambridge, UNITED KINGDOM, published by Humana.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. No dust jacket, as issued. This must be one of the clearest texts that provides an in depth introduction to this area of pharmacology-a joy for the interested reader! Excellent as new condition, perfect mint. Cancer drug discovery and development. First printing. (alk. paper) xii, 451 p. : ill. ; 26 cm. Includes bibliographical references and index.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $109.71, new condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Santa Clarita, CA, UNITED STATES, published 1996 by Humana.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $110.79, new condition, Sold by Just one more Chapter rated 3.0 out of 5 stars, ships from Miramar, FL, UNITED STATES, published 1996 by Humana.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $206.66, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2010 by Humana Press Inc..
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Print on demand Contains: Illustrations, black & white. Cancer Drug Discovery and Development . XII, 451 p. 7 illus. Intended for professional and scholarly audience.
Add this copy of Cancer Therapeutics: Experimental and Clinical Agents to cart. $206.66, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 1996 by Humana.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Sewn binding. Paper over boards. 451 p. Contains: Unspecified, Illustrations, black & white, Tables, black & white, Figures. Cancer Drug Discovery & Development.
